• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物转运体的多特异性:探究人源药物外排转运体ABCB1和ABCG2的抑制剂选择性

Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2.

作者信息

Cramer Joerg, Kopp Stephan, Bates Susan E, Chiba Peter, Ecker Gerhard F

机构信息

BioChemInformatics, Intervet Innovation GmbH, Zur Probstei, 55270 Schwabenheim, Germany.

出版信息

ChemMedChem. 2007 Dec;2(12):1783-8. doi: 10.1002/cmdc.200700160.

DOI:10.1002/cmdc.200700160
PMID:17994597
Abstract

Multidrug resistance transporters P-glycoprotein/ABCB1 and ABCG2 limit the effect of a large number of cytostatic and cytotoxic drugs by energy-dependent efflux. In experimental models, pump inhibitors reestablish sensitivity towards these drugs. Both transporters demonstrate remarkably broad and partly overlapping substrate specificity. Propafenone analogues are inhibitors of a large number of drug efflux pumps including P-glycoprotein and ABCG2 as well as the microbial pumps. Here the two human ABC transporters ABCB1 and ABCG2 have been studied with respect to interaction with this class of compounds. Data indicate that within the same chemical scaffold, selectivity indices span three orders of magnitude. Compounds with the highest selectivity indices contain a non-ionizable nitrogen atom. Qualitative and quantitative pharmacophore models indicate that hydrophobicity, the number of rotatable bonds, and the number of H-bond acceptors are key features for both activity and selectivity.

摘要

多药耐药转运蛋白P-糖蛋白/ABCB1和ABCG2通过能量依赖的外排作用限制了大量细胞生长抑制剂和细胞毒性药物的作用。在实验模型中,泵抑制剂可恢复对这些药物的敏感性。这两种转运蛋白均表现出非常广泛且部分重叠的底物特异性。普罗帕酮类似物是包括P-糖蛋白、ABCG2以及微生物泵在内的大量药物外排泵的抑制剂。在此,针对这一类化合物与两种人类ABC转运蛋白ABCB1和ABCG2的相互作用进行了研究。数据表明,在同一化学骨架内,选择性指数跨越三个数量级。具有最高选择性指数的化合物含有一个不可电离的氮原子。定性和定量药效团模型表明,疏水性、可旋转键的数量以及氢键受体的数量是活性和选择性的关键特征。

相似文献

1
Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2.药物转运体的多特异性:探究人源药物外排转运体ABCB1和ABCG2的抑制剂选择性
ChemMedChem. 2007 Dec;2(12):1783-8. doi: 10.1002/cmdc.200700160.
2
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.拉帕替尼(泰立沙,GW572016)通过抑制ATP结合盒亚家族B成员1和G成员2的活性来逆转癌细胞中的多药耐药性。
Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499.
3
A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.通过高通量流式细胞术揭示的一种选择性ATP结合盒亚家族G成员2外排抑制剂
J Biomol Screen. 2013 Jan;18(1):26-38. doi: 10.1177/1087057112456875. Epub 2012 Aug 24.
4
Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.尼洛替尼(AMN107,达希纳)通过抑制ABCB1/Pgp和ABCG2/BCRP/MXR转运蛋白的活性来逆转多药耐药性。
Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11.
5
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.有机阴离子转运多肽1B1介导吉美替尼和BNP1350的转运,并且可被几种经典的ATP结合盒(ABC)B1和/或ABCG2抑制剂抑制。
Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12.
6
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.达可替尼通过抑制 ABCB1 和 ABCG2 转运蛋白的外排活性来拮抗癌细胞中的多药耐药(MDR)。
Cancer Lett. 2018 May 1;421:186-198. doi: 10.1016/j.canlet.2018.01.021. Epub 2018 Jan 11.
7
Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.用于 ABCB1、ABCC1 和 ABCG2 转运蛋白的荧光底物用于流式细胞术评估外排抑制作用。
Anal Biochem. 2013 Jun 1;437(1):77-87. doi: 10.1016/j.ab.2013.02.018. Epub 2013 Mar 5.
8
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.表皮生长因子受体酪氨酸激酶抑制剂AG1478对ABCB1和ABCG2功能的抑制作用
Biochem Pharmacol. 2009 Mar 1;77(5):781-93. doi: 10.1016/j.bcp.2008.11.007. Epub 2008 Nov 18.
9
Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.刺猬信号通路抑制剂HhAntag691是ABCG2/BCRP和ABCB1/Pgp的强效抑制剂。
Neoplasia. 2009 Jan;11(1):96-101. doi: 10.1593/neo.81264.
10
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.舒尼替尼(索坦,SU11248)是一种小分子受体酪氨酸激酶抑制剂,可阻断ATP结合盒(ABC)转运蛋白P-糖蛋白(ABCB1)和ABCG2的功能。
Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29.

引用本文的文献

1
Molecular Modeling Studies to Probe the Binding Hypothesis of Novel Lead Compounds against Multidrug Resistance Protein ABCB1.分子建模研究探究新型先导化合物对多药耐药蛋白 ABCB1 的结合假说。
Biomolecules. 2024 Jan 16;14(1):114. doi: 10.3390/biom14010114.
2
Ligand- and Structure-based Approaches for Transmembrane Transporter Modeling.基于配体和结构的跨膜转运体建模方法。
Curr Drug Res Rev. 2024;16(2):81-93. doi: 10.2174/2589977515666230508123041.
3
Identification and Empiric Evaluation of New Inhibitors of the Multidrug Transporter P-Glycoprotein (ABCB1).
鉴定和经验评估多药转运蛋白 P-糖蛋白(ABCB1)的新型抑制剂。
Int J Mol Sci. 2023 Mar 10;24(6):5298. doi: 10.3390/ijms24065298.
4
Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.基于乳腺癌耐药蛋白(BCRP)及P-糖蛋白/乳腺癌耐药蛋白(P-gp/BCRP)双靶点的多药耐药调节剂研究的最新进展
Cancer Drug Resist. 2019 Sep 19;2(3):710-743. doi: 10.20517/cdr.2019.31. eCollection 2019.
5
Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators.克服多药耐药性:黄酮类和萜类含氮衍生物作为 ABC 转运蛋白调节剂。
Molecules. 2020 Jul 24;25(15):3364. doi: 10.3390/molecules25153364.
6
Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein.人、大鼠和小鼠 P-糖蛋白假定配体结合位点的种间比较。
Eur J Pharm Sci. 2018 Sep 15;122:134-143. doi: 10.1016/j.ejps.2018.06.022. Epub 2018 Jun 22.
7
Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.基于 DrugBank 的虚拟筛选发现两种药物可作为新型 BCRP 抑制剂。
SLAS Discov. 2017 Jan;22(1):86-93. doi: 10.1177/1087057116657513. Epub 2016 Jul 11.
8
Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).细微的结构差异引发普罗帕酮类似物对两种多特异性ABC转运蛋白的抑制活性:P-糖蛋白(P-gp)和乳腺癌耐药蛋白(BCRP)。
ChemMedChem. 2016 Jun 20;11(12):1380-94. doi: 10.1002/cmdc.201500592. Epub 2016 Mar 10.
9
Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies.P-糖蛋白(ABCB1)多特异性的分子基础:近期的生化与结构研究
Adv Cancer Res. 2015;125:71-96. doi: 10.1016/bs.acr.2014.10.003. Epub 2015 Jan 8.
10
Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.使用三维定量构效关系方法对尼罗替尼作为ATP结合盒式药物转运体和BCR-ABL激酶抑制剂进行药效团建模。
Mol Pharm. 2014 Jul 7;11(7):2313-22. doi: 10.1021/mp400762h. Epub 2014 Jun 5.